Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Acute lymphoblastic leukemia in older adults: curtain call for conventional chemotherapy?

Literature DB >> 34889389

Acute lymphoblastic leukemia in older adults: curtain call for conventional chemotherapy?

Abstract

Unlike younger adults with acute lymphoblastic leukemia (ALL), older adults are rarely cured due to a combination of intrinsic disease resistance and treatment-related toxicities. Novel therapeutics such as inotuzumab ozogamicin, blinatumomab, venetoclax, and ABL kinase inhibitors have high activity in ALL and are well tolerated by older adults. Frontline treatment regimens for older adults using novel therapeutics with reduction or omission of conventional chemotherapy are being developed with early results demonstrating high remission rates and lower toxicity, but long-term efficacy and toxicity data are lacking. Collaboration between academic and pharmaceutical stakeholders is needed to develop clinical trials to define the optimal treatment regimens for older adults with ALL.

Entities: Chemical

Mesh：

Substances：

Year: 2021 PMID： 34889389 PMCID： PMC8791151 DOI： 10.1182/hematology.2021000226

Source DB: PubMed Journal: Hematology Am Soc Hematol Educ Program ISSN： 1520-4383

37 in total

1. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.

Authors: Yves Chalandon; Xavier Thomas; Sandrine Hayette; Jean-Michel Cayuela; Claire Abbal; Françoise Huguet; Emmanuel Raffoux; Thibaut Leguay; Philippe Rousselot; Stéphane Lepretre; Martine Escoffre-Barbe; Sébastien Maury; Céline Berthon; Emmanuelle Tavernier; Jean-François Lambert; Marina Lafage-Pochitaloff; Véronique Lhéritier; Sylvie Chevret; Norbert Ifrah; Hervé Dombret
Journal: Blood Date: 2015-04-15 Impact factor: 22.113

2. Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission.

Authors: Ofir Wolach; Kristen E Stevenson; Martha Wadleigh; Daniel J DeAngelo; David P Steensma; Karen K Ballen; Robert J Soiffer; Joseph H Antin; Donna S Neuberg; Vincent T Ho; Richard M Stone
Journal: Am J Hematol Date: 2016-06-03 Impact factor: 10.047

3. Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia.

Authors: Amir T Fathi; Daniel J DeAngelo; Kristen E Stevenson; Jonathan E Kolitz; Julie D Asch; Philip C Amrein; Eyal C Attar; David P Steensma; Martha Wadleigh; Julia Foster; Christine Connolly; Ilene Galinsky; Craig E Devoe; Richard M Stone; Donna S Neuberg; Karen K Ballen
Journal: Cancer Date: 2016-05-12 Impact factor: 6.860

4. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.

Authors: Hagop Kantarjian; Farhad Ravandi; Nicholas J Short; Xuelin Huang; Nitin Jain; Koji Sasaki; Naval Daver; Naveen Pemmaraju; Joseph D Khoury; Jeffrey Jorgensen; Yesid Alvarado; Marina Konopleva; Guillermo Garcia-Manero; Tapan Kadia; Musa Yilmaz; Gautam Bortakhur; Jan Burger; Steven Kornblau; William Wierda; Courtney DiNardo; Alessandra Ferrajoli; Jovitta Jacob; Rebecca Garris; Susan O'Brien; Elias Jabbour
Journal: Lancet Oncol Date: 2018-01-16 Impact factor: 41.316

5. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.

Authors: R A Larson; R K Dodge; C A Linker; R M Stone; B L Powell; E J Lee; P Schulman; F R Davey; S R Frankel; C D Bloomfield; S L George; C A Schiffer
Journal: Blood Date: 1998-09-01 Impact factor: 22.113

6. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.

Authors: R A Larson; R K Dodge; C P Burns; E J Lee; R M Stone; P Schulman; D Duggan; F R Davey; R E Sobol; S R Frankel
Journal: Blood Date: 1995-04-15 Impact factor: 22.113

7. Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.

Authors: Robin Foà; Renato Bassan; Antonella Vitale; Loredana Elia; Alfonso Piciocchi; Maria-Cristina Puzzolo; Martina Canichella; Piera Viero; Felicetto Ferrara; Monia Lunghi; Francesco Fabbiano; Massimiliano Bonifacio; Nicola Fracchiolla; Paolo Di Bartolomeo; Alessandra Mancino; Maria-Stefania De Propris; Marco Vignetti; Anna Guarini; Alessandro Rambaldi; Sabina Chiaretti
Journal: N Engl J Med Date: 2020-10-22 Impact factor: 91.245

8. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

Authors: Hagop M Kantarjian; Daniel J DeAngelo; Matthias Stelljes; Giovanni Martinelli; Michaela Liedtke; Wendy Stock; Nicola Gökbuget; Susan O'Brien; Kongming Wang; Tao Wang; M Luisa Paccagnella; Barbara Sleight; Erik Vandendries; Anjali S Advani
Journal: N Engl J Med Date: 2016-06-12 Impact factor: 91.245

9. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors: Farhad Ravandi
Journal: Blood Date: 2018-11-15 Impact factor: 22.113

10. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia.

Authors: Susan O'Brien; Deborah A Thomas; Farhad Ravandi; Stefan Faderl; Sherry Pierce; Hagop Kantarjian
Journal: Cancer Date: 2008-10-15 Impact factor: 6.860

1 in total

Review 1. CAR T-Cell Therapy in the Older Person: Indications and Risks.

Authors: Geoffrey Shouse; Alexey V Danilov; Andy Artz
Journal: Curr Oncol Rep Date: 2022-04-14 Impact factor: 5.945

1 in total